Author:
Fedenko E S,Petrovskaya T Yu,Lopatin A S,Sergeeva T A
Reference11 articles.
1. Bousquet J. Requirements for medication commonly used in the treatment of allergic rhinitis. Allergy, 2003, v. 58, p.192197.
2. Ciprandi G., Cirillo I., Vizzaccaro A., Tosca M.A. Levoceti rizine improves nasal obstruction and modulates cytokine pat tern in patients with seasonal allergic rhinitis: a pilot study. Clin. Exp. Allergy, 2004, v. 34, Nо. 6, p. 958964.
3. Lipworth B.J., Wilson A.M., Haggart K., Sims E.J. Differnc es in vitro H1receptor antagonist potency with fexofenadine and desloratadine do not determine effects on nasal conges tion in seasonal allergic rhinitis. Allergy, 2002, v. 57, s. 73, p. 1015.
4. Meltzer E.O., Jalowayski .AA., Vogt K. et al. Effect of deslor atadine therapy on symptom scores and measures of nasal pa tency in seasonal allergic rhinitis: results of a singlecenter, placebocontrolled trial. Ann. Allergy Asthma Immunol, 2006, v. 96, No. 2, p. 363368.
5. Riechelmann H. Oral second generation antihistamines in allergic rhinitis. Laryngorhinootologie, 2005, v. 84, No. 1, p. 3041.